The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

ProKidney Corp. (NASDAQ:PROK) is one of the small-cap stocks with potential to rise 1000 percent. The company’s main story centers on rilparencel, its experimental cell therapy for patients with advanced chronic kidney disease and type 2 diabetes. On May 15, ProKidney said it remained on track to finish enrolling patients for an important part of its PROACT 1 late-stage trial in mid-2026, with key kidney-function results expected in the second quarter of 2027.

The trial is important because the FDA has already agreed that ProKidney can use a kidney-function measure called eGFR slope as the main basis for seeking accelerated approval. In simple terms, eGFR slope tracks how quickly a patient’s kidney function is worsening over time. ProKidney also pointed to earlier Phase 2 data from the REGEN-007 study, where one patient group showed a 4.6 mL/min/1.73m² improvement in annual kidney-function decline after treatment compared with the period before injection. The company ended the first quarter with $224.9 million in cash, cash equivalents, and marketable securities, which it expects to fund operations into mid-2027.

ProKidney Corp. (NASDAQ:PROK) is a late clinical-stage biotechnology company developing rilparencel, a cell therapy made from a patient’s own kidney cells, for advanced chronic kidney disease in patients with type 2 diabetes.

While we acknowledge the potential of PROK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.